CN115054614A - 一种根治面部痤疮的净颜膏及其制备方法 - Google Patents
一种根治面部痤疮的净颜膏及其制备方法 Download PDFInfo
- Publication number
- CN115054614A CN115054614A CN202210640630.XA CN202210640630A CN115054614A CN 115054614 A CN115054614 A CN 115054614A CN 202210640630 A CN202210640630 A CN 202210640630A CN 115054614 A CN115054614 A CN 115054614A
- Authority
- CN
- China
- Prior art keywords
- facial
- acne
- lincomycin
- cleansing cream
- radically treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001815 facial effect Effects 0.000 title claims abstract description 28
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 16
- 206010000496 acne Diseases 0.000 title claims abstract description 16
- 239000006071 cream Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims abstract description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 16
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 16
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960004125 ketoconazole Drugs 0.000 claims abstract description 16
- 229960004194 lidocaine Drugs 0.000 claims abstract description 16
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims abstract description 16
- 229960005287 lincomycin Drugs 0.000 claims abstract description 16
- 239000002674 ointment Substances 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- BITDLWAQPKSXTF-UHFFFAOYSA-M 1-[(3-nitrophenyl)methoxymethyl]pyridin-1-ium;chloride Chemical compound [Cl-].[O-][N+](=O)C1=CC=CC(COC[N+]=2C=CC=CC=2)=C1 BITDLWAQPKSXTF-UHFFFAOYSA-M 0.000 claims abstract description 11
- 229960002581 moroxydine hydrochloride Drugs 0.000 claims abstract description 11
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims abstract description 8
- 229940106164 cephalexin Drugs 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims description 6
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 4
- 229960004703 clobetasol propionate Drugs 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000000922 anti-bactericidal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种根治面部痤疮的净颜膏及其制备方法，包括以下重量份配比的原料药：10％双氧水、5％林可霉素利多卡因凝胶、10％复方酮康唑软膏、5％头孢氨苄和5％盐酸吗啉胍剂片。本发明的净颜膏对皮肤无任何刺激性，治疗方式健康，造价便宜，能够有效根治痤疮问题。
Description
技术领域
本发明涉及医药配方技术领域，具体为一种根治面部痤疮的净颜膏及其制备方法。
背景技术
面部各类痤疮成为困扰人们皮肤问题的难以解决的困扰，市面上治疗机构鱼龙混杂，现有的治疗手段通常无法根治痤疮的反复发生，治疗技术存在盲目性、创伤性，且皮损过大，通常患者原本治疗痤疮，但是外力使用过大，造成额外损伤、真皮层伤疤等不可逆的伤害，皮肤还会随着过度治疗发展为依赖性皮炎，令人形象受损。本发明的配方可以令皮肤形成一个完整的新陈代谢周期，使皮肤问题从根源得到解决，修复至健康肌肤，断根不再反复。
发明内容
针对上述存在的技术不足，本发明的目的是提供一种根治面部痤疮的净颜膏及其制备方法，以解决背景技术中提出的问题。
为解决上述技术问题，本发明采用如下技术方案：
本发明提供一种根治面部痤疮的净颜膏及其制备方法，包括以下重量份配比的原料药：10％双氧水、5％林可霉素利多卡因凝胶、10％复方酮康唑软膏、 5％头孢氨苄和5％盐酸吗啉胍剂片。
优选地，所述的林可霉素利多卡因凝胶包括林可霉素和利多卡因。
优选地，所述的复方酮康唑软膏包括含酮康唑和丙酸氯倍他索。
一种根治面部痤疮的净颜膏的制备方法，包括如下步骤：
(1)配比检验：检测各原料的配比、重量是否符合要求；
(2)将盐酸吗啉胍剂片研磨成粉；
(3)调配：将双氧水、林可霉素利多卡因凝胶、复方酮康唑软膏、头孢氨苄和盐酸吗啉胍剂片加入搅拌机中，混合搅拌均匀后，进行灭菌处理，再装入膏管中封存。
本发明的有益效果在于：
本发明的净颜膏对皮肤无任何刺激性，治疗方式健康，造价便宜，能够有效根治痤疮问题。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例：
本发明提供了一种根治面部痤疮的净颜膏，包括以下重量份配比的原料药：10％双氧水、5％林可霉素利多卡因凝胶、10％复方酮康唑软膏、5％头孢氨苄和5％盐酸吗啉胍剂片。
进一步的，所述的林可霉素利多卡因凝胶包括林可霉素和利多卡因。
每克林可霉素利多卡因凝胶含林可霉素5毫克，利多卡因4毫克。
进一步的，所述的复方酮康唑软膏包括含酮康唑和丙酸氯倍他索。
每克复方酮康唑软膏含酮康唑10毫克和丙酸氯倍他索0.5毫克。
一种根治面部痤疮的净颜膏的制作方法，包括如下步骤：
(1)配比检验：检测各原料的配比、重量是否符合要求；
(2)将盐酸吗啉胍剂片研磨成粉；
(3)调配：将双氧水、林可霉素利多卡因凝胶、复方酮康唑软膏、头孢氨苄和盐酸吗啉胍剂片加入搅拌机中，混合搅拌均匀后，进行灭菌处理，再装入膏管中封存。
医用双氧水主要用于消毒，化脓性球菌消炎；
林可霉素利多卡因凝胶主要用于解决皮肤创面，创伤后的外部感染；
复方酮康唑软膏用于治疗瘙痒，体癣，外部感染；
头孢氨苄用于消炎杀菌，减少外部感染；
盐酸吗啉胍剂片用于抑菌；
本发明的净颜膏为每支50克，外用药膏，每日三次涂抹于外患部，消炎杀菌。
显然，本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样，倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内，则本发明也意图包含这些改动和变型在内。
Claims (4)
1.一种根治面部痤疮的净颜膏，其特征在于，包括以下重量份配比的原料药：10％双氧水、5％林可霉素利多卡因凝胶、10％复方酮康唑软膏、5％头孢氨苄和5％盐酸吗啉胍剂片。
2.如权利要求1所述的一种根治面部痤疮的净颜膏，其特征在于，所述的林可霉素利多卡因凝胶包括林可霉素和利多卡因。
3.如权利要求1所述的一种根治面部痤疮的净颜膏，其特征在于，所述的复方酮康唑软膏包括含酮康唑和丙酸氯倍他索。
4.如权利要求1所述的一种根治面部痤疮的净颜膏的制备方法，其特征在于，包括如下步骤：
(1)配比检验：检测各原料的配比、重量是否符合要求；
(2)将盐酸吗啉胍剂片研磨成粉；
(3)调配：将双氧水、林可霉素利多卡因凝胶、复方酮康唑软膏、头孢氨苄和盐酸吗啉胍剂片加入搅拌机中，混合搅拌均匀后，进行灭菌处理，再装入膏管中封存。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210640630.XA CN115054614A (zh) | 2022-06-07 | 2022-06-07 | 一种根治面部痤疮的净颜膏及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210640630.XA CN115054614A (zh) | 2022-06-07 | 2022-06-07 | 一种根治面部痤疮的净颜膏及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115054614A true CN115054614A (zh) | 2022-09-16 |
Family
ID=83200853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210640630.XA Pending CN115054614A (zh) | 2022-06-07 | 2022-06-07 | 一种根治面部痤疮的净颜膏及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115054614A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001163783A (ja) * | 1999-09-28 | 2001-06-19 | Shoei:Kk | 皮膚疾患治療用外用剤 |
| CN1634115A (zh) * | 2004-11-17 | 2005-07-06 | 姜凤龙 | 清痘洁净霜 |
| CN113384594A (zh) * | 2021-06-19 | 2021-09-14 | 李奇 | 一种祛痘药物配方及其药物制备装置 |
-
2022
- 2022-06-07 CN CN202210640630.XA patent/CN115054614A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001163783A (ja) * | 1999-09-28 | 2001-06-19 | Shoei:Kk | 皮膚疾患治療用外用剤 |
| CN1634115A (zh) * | 2004-11-17 | 2005-07-06 | 姜凤龙 | 清痘洁净霜 |
| CN113384594A (zh) * | 2021-06-19 | 2021-09-14 | 李奇 | 一种祛痘药物配方及其药物制备装置 |
Non-Patent Citations (1)
| Title |
|---|
| 张卫华: "《穴位用药治百病》", 人民军医出版社, pages: 436 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103191284A (zh) | 一种应用于浅表性创伤的龙血竭喷雾膜剂及其制备工艺 | |
| CN114099604A (zh) | 一种具有预防疤痕功能的生物敷料及其制备方法 | |
| CN105749333A (zh) | 一种透明质酸医用敷料及其制备方法 | |
| CN108888759A (zh) | 一种用于伤口愈合的组合物 | |
| CN115054614A (zh) | 一种根治面部痤疮的净颜膏及其制备方法 | |
| CN101884642A (zh) | 一种治疗痤疮的复方乳膏及其制备方法 | |
| WO2013078754A1 (zh) | 一种含二氧化氯的生发溶液及其制备和使用方法 | |
| CN104306397A (zh) | 一种抗菌外用软膏及其制作方法 | |
| CN102846610A (zh) | 皮肤局部外用镇痛复方制剂组合物及其制备方法 | |
| CN104382998A (zh) | 一种卡波姆凝胶及其制备方法 | |
| CN111803622A (zh) | 一种口腔溃疡液态修复膜 | |
| CN101361938A (zh) | 含天然珊瑚姜油的冻疮膏 | |
| CN1062128C (zh) | 除癣膏 | |
| CN101422430B (zh) | 酮康唑麝香草酚治皮癣溶液 | |
| CN116327669B (zh) | 一种具有修护皮肤屏障功能的祛痘组合物及其制备方法 | |
| CN110974810B (zh) | 成膜型护创液及其制备方法与应用 | |
| CN115634251A (zh) | 一种芦荟凝胶创伤外用药的制备方法 | |
| CN101926825A (zh) | 一种红油膏药品及其配制方法 | |
| CN113940948A (zh) | 一种烧伤药膏及其制备方法 | |
| CN1086125C (zh) | 一种治疗癣病的外用药 | |
| CN101716191A (zh) | 一种治疗褥疮的外敷中药组合物 | |
| CN1061863C (zh) | 一种治疗银屑病的外用药 | |
| CN116966208A (zh) | 一种抗菌凝胶及其制备方法 | |
| CN1712009A (zh) | 一种治疗痤疮、青春痘、酒糟鼻、毛囊炎的外用药液 | |
| CN117771269A (zh) | 一种用于治疗指甲病的药膏 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |